Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Cerebral Edema
Conditions
Interventions
Balovaptan
Placebo
Locations
1
United States
CPMC Comprehensive Stroke Care Center
San Francisco, California, United States
Start Date
June 22, 2022
Primary Completion Date
November 17, 2022
Completion Date
November 17, 2022
Last Updated
August 7, 2023
NCT07253181
NCT06990867
NCT07001267
NCT03153683
NCT07371624
NCT05847699
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions